Drugs / QLS-101
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05495269 | Nov 2022 → Jan 2023 | Sturge-Weber syndrome, glaucoma with elevated episcleral venous pressure, ocular hypertension | Qlaris Bio, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04947124 | Oct 2021 → Jun 2022 | Sturge-Weber syndrome, congenital glaucoma, ocular hypertension | Qlaris Bio, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04857827 | Sep 2021 → Aug 2022 | low tension glaucoma | Qlaris Bio, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04830397 | Mar 2021 → Feb 2022 | ocular hypertension, open-angle glaucoma | Qlaris Bio, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04947124 ↗ |
| Route | Other | “ocular administration (eye drop)” NCT05495269 ↗ |